Impact of Adalimumab (Humira) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice

Trial Profile

Impact of Adalimumab (Humira) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use
  • Acronyms IDEA
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 20 Nov 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 05 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 23 Jan 2014 Planned End Date changed from 1 Dec 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top